Abstract:The interaction of iron and oxygen is an integral part of the development of life on Earth. Nonetheless, this unique chemistry continues to fascinate and puzzle, leading to new biological ventures. In 2012, a Columbia University group recognized this interaction as a central event leading to a new type of regulated cell death named "ferroptosis." The major feature of ferroptosis is the accumulation of lipid hydroperoxides due to (1) dysfunctional antioxidant defense and/or (2) overwhelming oxidative stress, which most frequently coincides with increased content of free labile iron in the cell. This is normally prevented by the canonical anti-ferroptotic axis comprising the cystine transporter xCT, glutathione (GSH), and GSH peroxidase 4 (GPx4). Since ferroptosis is not a programmed type of cell death, it does not involve signaling pathways characteristic of apoptosis. The most common way to prove this type of cell death is by using lipophilic antioxidants (vitamin E, ferrostatin-1, etc.) to prevent it. These molecules can approach and detoxify oxidative damage in the plasma membrane. Another important aspect in revealing the ferroptotic phenotype is detecting the preceding accumulation of lipid hydroperoxides, for which the specific dye BODIPY C11 is used. The present manuscript will show how ferroptosis can be induced in wild-type medulloblastoma cells by using different inducers: erastin, RSL3, and iron-donor. Similarly, the xCT-KO cells that grow in the presence of NAC, and which undergo ferroptosis once NAC is removed, will be used. The characteristic "bubbling" phenotype is visible under the light microscope within 12-16 h from the moment of ferroptosis triggering. Furthermore, BODIPY C11 staining followed by FACS analysis to show the accumulation of lipid hydroperoxides and consequent cell death using the PI staining method will be used. To prove the ferroptotic nature of cell death, ferrostatin-1 will be used as a specific ferroptosis-preventing agent.

Profiling of Protein Carbonylations in Ferroptosis by Chemical Proteomics

Quantitative Profiling of Protein Carbonylations in Ferroptosis by an Aniline-Derived Probe.

Targeting Ferroptosis in Breast Cancer

Quantitative reactive cysteinome profiling reveals a functional link between ferroptosis and proteasome-mediated degradation

Reactivity-Based Probe of the Iron(II)-Dependent Interactome Identifies New Cellular Modulators of Ferroptosis

Proteomic Shift in Mouse Embryonic Fibroblasts Pfa1 during Erastin, ML210, and BSO-Induced Ferroptosis

Protein modification and degradation in ferroptosis

Proteomic analysis of ferroptosis pathways reveals a role of CEPT1 in suppressing ferroptosis

The Chemistry and Biology of Ferroptosis

Probing Lipid Peroxidation in Ferroptosis: Emphasizing the Utilization of C11-BODIPY-Based Protocols

LC-MS-Based Redox Phosphoipidomics Analysis in Ferroptosis.

Mass spectrometry-based approaches to explore metabolism regulating ferroptosis

Chemoproteomic Profiling of Targets of Lipid-Derived Electrophiles by Bioorthogonal Aminooxy Probe

Recent advances in small-molecule fluorescent probes for studying ferroptosis

Chemoproteomic Profiling of Erastin-Interacting Proteins

Identification of essential sites of lipid peroxidation in ferroptosis

Understanding the unique mechanism of ferroptosis: a promising therapeutic target

Revealing the Ferroptotic Phenotype of Medulloblastoma

Fluorescent probes for ferroptosis bioimaging: advances, challenges, and prospects

Ferroptosis in health and disease

Ferroptosis in life: To be or not to be